Resumen

GAYOSO, Belén et al. Species and sensitivity to antifungals of Candida spp. strains isolated from the oral cavity of patients with HIV from Paraguay. Mem. Inst. Investig. Cienc. Salud [online]. 2021, vol.19, n.3, pp.12-24. ISSN 1812-9528.  https://doi.org/10.18004/mem.iics/1812-9528/2021.019.03.12.

Candida albicans is the most isolated yeast from the oral cavity of people with HIV. However, the use of antifungals has increased the isolation of non-C. albicans resistant species or those with reduced sensitivity. The objective of the study was to determine the Candida species and the sensitivity to antifungals of isolates from the oral cavity of patients with HIV who attended the Institute of Tropical Medicine between July and December 2019. The yeasts were plated in Candida Chromogenic Agar (CONDA®, Spain) for presumptive identification. Green colonies were identified by duplex PCR and those with different staining or negative PCR using the commercial VITEK®2 system. The antifungal susceptibility of C. albicans was determined by VITEK®2, and non albicans by the disk diffusion method. Of 278 yeasts, C. albicans was isolated in 70.9 %, followed by C. tropicalis (8.3 %) and C. krusei (5 %). C. albicans presented 93 % sensitivity and 2 % dose-dependent sensitivity to fluconazole; 87 % sensitive and 3 % intermediate sensitivity to voriconazole; 97, 98, and 100 % sensitive to flucytosine, amphotericin B, and echinocandins, respectively. C. parapsilosis and C. tropicalis did not register resistance to fluconazole and voriconazole. All C. glabrata isolates were dose-dependently sensitive to fluconazole and all C. krusei isolates were sensitive to voriconazole. The oral carriage of Candida spp. resistant to azoles may lead to therapeutic failures in HIV patients who develop oropharyngeal candidiasis.

Palabras clave : Candida; oral cavity; HIV; antifungal.

        · resumen en Español     · texto en Español     · Español ( pdf )